Scholarlink

With 14–24% of the population affected, Australia has among the highest rates of allergic diseases globally. However, many patient needs are not adequately addressed across this vast continent with its biogeographically diverse exposures to pollen, insect, and seafood allergen sources. The 2020 Commonwealth Inquiry in Allergy and Anaphylaxis arrived at 24 recommendations to improve education, care, and outcomes for allergy patients nationally. This underpinned a partnership between the peak professional body; Australasian Society of Clinical Immunology and Allergy, and the patient advocacy foundation; Allergy and Anaphylaxis Australia to form the National Allergy Council, and a collaboration with the Australian Digital Health Agency on projects to increase harmonization, quality, and sharing of allergy notification data. The National Allergy Centre of Excellence was also established to build systems and capabilities that accelerate allergy research. With segregated responsibilities for healthcare across tiers of government, the landscape for digital health systems here is complex with a plethora of stakeholders involved in guiding and governing national standardization, linking and integration of health datasets primarily for safety and quality purposes. Views of the national prevalence of allergies and the scope of allergy research in Australia can be garnered from a National Health Survey, the NACE allergy studies directory, and the Australian and New Zealand Clinical Trials Registry. Australia has been rapid in its adoption of digital approaches including virtual care platforms, transition to electronic medical records, clinical registries of adverse drug reactions (AusCAR, iNAAN), response to biologics for allergic respiratory conditions (e.g., ASAR), mHealth applications to share pollen exposure information, symptom surveys (e.g., AusPollen and AirRater), and manage health (e.g., MASKair, AllergyPal). With these rapidly emerging and sophisticated digital health capabilities, there are an ongoing opportunities and challenges to navigation of the digital health landscape to derive new insights can inform ways to more fully and equitably improve the lives of allergy patients in this country.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Landscape of Digital Health Approaches to Allergy in Australia

  • 章节

  • 发表日期：

    2025年

查看全文
  • Janet M. Davies

摘要

With 14–24% of the population affected, Australia has among the highest rates of allergic diseases globally. However, many patient needs are not adequately addressed across this vast continent with its biogeographically diverse exposures to pollen, insect, and seafood allergen sources. The 2020 Commonwealth Inquiry in Allergy and Anaphylaxis arrived at 24 recommendations to improve education, care, and outcomes for allergy patients nationally. This underpinned a partnership between the peak professional body; Australasian Society of Clinical Immunology and Allergy, and the patient advocacy foundation; Allergy and Anaphylaxis Australia to form the National Allergy Council, and a collaboration with the Australian Digital Health Agency on projects to increase harmonization, quality, and sharing of allergy notification data. The National Allergy Centre of Excellence was also established to build systems and capabilities that accelerate allergy research. With segregated responsibilities for healthcare across tiers of government, the landscape for digital health systems here is complex with a plethora of stakeholders involved in guiding and governing national standardization, linking and integration of health datasets primarily for safety and quality purposes. Views of the national prevalence of allergies and the scope of allergy research in Australia can be garnered from a National Health Survey, the NACE allergy studies directory, and the Australian and New Zealand Clinical Trials Registry. Australia has been rapid in its adoption of digital approaches including virtual care platforms, transition to electronic medical records, clinical registries of adverse drug reactions (AusCAR, iNAAN), response to biologics for allergic respiratory conditions (e.g., ASAR), mHealth applications to share pollen exposure information, symptom surveys (e.g., AusPollen and AirRater), and manage health (e.g., MASKair, AllergyPal). With these rapidly emerging and sophisticated digital health capabilities, there are an ongoing opportunities and challenges to navigation of the digital health landscape to derive new insights can inform ways to more fully and equitably improve the lives of allergy patients in this country.